Roche Faces Probe On Claims It Derailed Biosimilar Herceptin
Executive Summary
Did Roche engage in abusive market conduct aimed at keeping trastuzumab biosimilar versions at bay in India? The Competition Commission of India has sought a detailed investigation into a string of serious allegations brought about by Biocon and Mylan and has held that some of the Swiss firm’s actions prima facie appear to be aimed at adversely affecting the penetration of biosimilars in the country.
You may also be interested in...
What’s In Store For Roche’s New India Boss?
Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.
Biocon Cautiously Optimistic On Earnings Prospects Amid Slower Approvals
India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.
Biocon Cautiously Optimistic On Earnings Prospects Amid Slower Approvals
India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.
Need a specific report? 1000+ reports available
Buy Reports